DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury

Laboratory Investigation

Volumn 96, Issue 5, 2016, Pages 547-560

  Eun Lee, Jee ^a   Kim, Jung Eun ^b   Lee, Mi Hwa ^b   Song, Hye Kyoung ^b   Ghee, Jung Yeon ^b   Kang, Young Sun ^b   Min, Hye Sook ^b   Kim, Hyun Wook ^a   Cha, Jin Joo ^b   Han, Jee Young ^c   Han, Sang Youb ^d   Cha, Dae Ryong ^b  

^a Wonkwang University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Inha University   (South Korea)

^d Inje University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; ABC TRANSPORTER A1; ADIPONECTIN; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; CALVASCULIN; CHEMOATTRACTANT; CREATININE; DA 1229; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOXORUBICIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; OSTEOPONTIN; UNCLASSIFIED DRUG; UVOMORULIN; 4-(3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL)-3-(TERT-BUTOXYMETHYL)PIPERAZIN-2-ONE; AUTACOID; CCL2 PROTEIN, MOUSE; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, MOUSE; MEMBRANE PROTEIN; PIPERAZINE DERIVATIVE; PROTECTIVE AGENT; SPP1 PROTEIN, MOUSE;

ADRIAMYCIN-INDUCED NEPHROPATHY; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL DAMAGE; CELL INFILTRATION; CELL VIABILITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; FAT MASS; FATTY LIVER; FIBROSING ALVEOLITIS; FOOD INTAKE; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY STRUCTURE; MACROPHAGE; MALE; METABOLIC PARAMETERS; MOUSE; MTT ASSAY; NONHUMAN; PHYSICAL PARAMETERS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEINURIA; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; URINARY EXCRETION; URINE VOLUME; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG EFFECT; GENETICS; INJURIES; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; URINE;

ANIMALS; CHEMOKINE CCL2; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DOXORUBICIN; INFLAMMATION MEDIATORS; KIDNEY; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; OSTEOPONTIN; PIPERAZINES; PODOCYTES; PROTECTIVE AGENTS;

EID: 84964745293     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2016.34     Document Type: Article

References (37)

1. Martin JH, Deacon CF, Gorrell MD et al. Incretin-based therapies- review of the physiology, pharmacology and emerging clinical experience. Intern Med J 2011;41:299-307.
2. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagonlike peptide-1 in the mouse. Endocrinology 1994;134:2156-2164.
3. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137:2968-2978.
4. Hirata K, Kume S, Araki S et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009;380:44-49.
5. Sivertsen J, Rosenmeier J, Holst JJ et al. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012;9:209-222.
6. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013;62:3316-3323.
7. Sharkovska Y, Reichetzeder C, Alter M et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J Hypertens 2014;32:2211-2223.
8. Mori H, Okada Y, Arao T et al. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig 2014;5:313-319.
9. Marques C, Mega C, Gonçalves A et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm 20142014; 538737.
10. Nakashima S, Matsui T, Takeuchi M et al. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res 2014;46:717-721.
11. Kanasaki K, Shi S, Kanasaki M et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014;63:2120-2031.
12. Kodera R, Shikata K, Takatsuka T et al. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun 2014;443: 828-833.
13. Mega C, de Lemos ET, Vala H et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 20112011; 162092.
14. Liu WJ, Xie SH, Liu YN et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012;340:248-255.
15. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type ii diabetes. J Clin Invest 1997;99: 342-348.
16. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;54:1626-1634.
17. Patrakka J, Kestila M, Wartiovaara J et al. Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients. Kidney Int 2000;58:972-980.
18. Koziell A, Grech V, Hussain S et al. Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. Hum Mol Genet 2002;11:379-388.
19. Doublier S, Ruotsalainen V, Salvidio G et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 2001;158:1723-1731.
20. Nistala R, Habibi J, Aroor A et al. DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring) 2014;22:2172-2179.
21. Tinoco AD, Tagore DM, Saghatelian A. Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform. J Am Chem Soc 2010;132:3819-3830.
22. Kim HW, Lee JE, Cha JJ et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology 2013;154:3366-3376.
23. Ma LJ, Nakamura S, Aldigier JC et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005;16:966-976.
24. Bonegio RG, Fuhro R, Wang Z et al. Rapamycin ameliorates proteinuria associated tubulointerstitial fibrosis inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005;16: 2063-2072.
25. Kim HJ, Kwak WY, Min JP et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2011;21:3809-3812.
26. Cho JM, Jang HW, Cheon H et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. Diabetes Res Clin Pract 2011;91:72-79.
27. Kim MK, Chae YN, Kim HD et al. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci 2012;90:21-29.
28. Kim TE, Lim KS, Park MK et al. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. Clin Ther 2012;34:1986-1998.
29. Stefanovic V, Ardaillou N, Vlahovic P et al. Interferon-gamma induces dipeptidylpeptidase iv expression in human glomerular epithelial cells. Immunology 1993;80:465-470.
30. Yang J, Campitelli J, Hu G et al. Increase in dpp-iv in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 2007;81:272-279.
31. Balaban YH, Korkusuz P, Simsek H et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007;6:242-250.
32. Nistala R, Habibi J, Lastra G et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology 2014;155: 2266-2276.
33. Jung ES, Kim JH, Kim SH et al. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy. Eur J Pharmacol 2015;761:116-124.
34. Alter ML, Ott IM, von Websky K et al. Dpp-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012;36:119-130.
35. Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 2011;16:30-38.
36. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999;56:393-405.
37. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007;106:26-31.